Cooperation between relyon plasma GmbH and Viromed Medical GmbH
Plasma in medicine
For several years now, relyon plasma has been working intensively on the topic of
cold atmospheric pressure plasma in medical technology and medicine. We are
therefore particularly proud to announce the co-operation with our customer
Viromed Medical GmbH.
Regensburg. Relyon plasma GmbH, a subsidiary of TDK Electronics AG, and Viromed Medical GmbH are jointly researching the use of cold atmospheric pressure plasma in medicine. Here, relyon plasma is responsible for developing the technology that utilizes plasma. Within the co-operation, Viromed is responsible for the approval of the device and its distribution.
Viromed Medical GmbH has been involved in basic research into viruses and bacteria since 2004 and is revolutionizing medical technology using cold atmospheric plasma in room air purification, wound healing and intensive care medicine.
Plasma in dermatology
Viromed has developed the ViroCAP® system based on relyon plasma’s piezoelectric direct discharge technology. This device is designed to use cold atmospheric pressure plasma in dermatology. Uwe Perbandt, CEO of Viromed, describes the treatment approach as follows: ‘Treatment with the ViroCAP® activates the body’s own regeneration processes. This process occurs with the help of reactive species that stimulate cell metabolism. In this way, the entire wound healing process is activated.’
At Arab Health, the global healthcare exhibition in Dubai, from 27th – 30th January 2025, relyon plasma will be presenting the ViroCAP® system from Viromed for the first time in addition to its existing products PiezoBrush PZ3 and MediPlas system.
MediPlas ozone generator in infection research
In addition, the two companies, together with the Hannover Medical School and the expert network BREATH (Biomedical Research in End-stage and Obstructive Lung Disease Hannover) from the German Centre for Lung Research (DZL) and the Helmholtz Institute for Infection Research (HZI), are investigating the disinfecting effect of plasma using the MediPlas ozone generator in infection research. The aim of the co-operation is to investigate the safety and effectiveness of cold plasma for eliminating bacteria in the respiratory tract to prevent ventilator-associated pneumonia (VAP). The aim is to develop a novel, non-antibiotic preventive measure to protect patients from this serious complication.
As a partner of Viromed, relyon plasma will establish the prototypes for the application and ensure the standardized generation of cold plasma as well as its characterization and consistency in the execution of the tests. Viromed Medical AG holds the exploitation rights.
Simona Lerach, Managing Director of relyon plasma GmbH, summarizes the cooperation: ‘We are delighted to have partnered with Viromed, an innovative company in the medical field that is conducting in-depth research and development into the use of cold atmospheric pressure plasma in medicine with our components.’
You can download the entire press release here.
